Clinical trials: Post-ERCP Acute Pancreatitis.
Post-ERCP Acute Pancreatitis
A Prospective Trial of Aggressive Hydration Strategy to Reduce Post-ERCP Pancreatitis
Postendoscopic retrograde cholangiopancreatography pancreatitis is the most frequent and serious complication of ERCP procedures, occurring in approximately 5-15% of unselected patients.
- Trial name
- NCT02308891
- Testing
- lactated Ringer's solution (vigorous hydration arm), lactated Ringer's solution (standard hydration arm), endoscopic retrograde cholangiopancreatography (ERCP)
- Where
- 3 sites in South Korea
- Volunteers
- 510 people, healthy volunteers welcome
- Sponsor
- Dankook University
Post-ERCP Acute Pancreatitis, Epinephrine
Effect of Papillary Epinephrine Spraying for the Prevention of Post-ERCP Pancreatitis in Patients Received Octreotide
Post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP) is the most common complication with high costs, significant morbidity and even mortality.
- Trial name
- NCT03756116
- Testing
- Epinephrine sprayed on the papilla, Saline sprayed on the papilla
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- The Second Hospital of Nanjing Medical University
Post-ERCP Acute Pancreatitis
PAN-PROMISE to Detect Post-ERCP Pancreatitis Symptoms
The aim of this study is to use a validated patient-reported outcome measure to evaluate how many patients have symptoms of pancreatitis after ERCP and how it correlates with their quality of life and productivity.
- Trial name
- PAN-PROMISE (NCT05310409)
- Where
- 2 sites in United States
- Volunteers
- 700 people
- Sponsor
- University of Pennsylvania
Acute Pancreatitis
Efficacy of Administration of Somatostatin in the Prevention of Post-endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis
Acute pancreatitis is the most frequent (5-10%) and severe complication after endoscopic retrograde cholangiopancreatography (ERCP), that could require of surgical intervention and lead to death.
- Trial name
- crepsmt1 (NCT01060826)
- Testing
- fisiologic serum, somatostatin, intravenous bolus, somatostatin
- Where
- 2 sites in Spain
- Volunteers
- 510 people
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Pancreatitis, Acute, Cholangiopancreatography, Endoscopic Retrograde
Efficacy and Safety of Parecoxib vs. Indomethacin in Preventing Post-ERCP Pancreatitis
This study aims to evaluate the efficacy and safety of parecoxib versus indomethacin in preventing post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP).
- Trial name
- PRECISE (NCT06623513)
- Testing
- Parecoxib Sodium, Indomethacin suppository
- Volunteers
- 100 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Post-ERCP Acute Pancreatitis
Prediction of PEP Based on the Appearance of the Major Duodenal Papilla
This observational, prospective study aims at evaluating how the occurrence of post-Endoscopic Retrograde CholangioPancreatography (ERCP) acute pancreatitis (PEP) could be influenced by difficult biliary cannulation that might be…
- Trial name
- PredERCP (NCT05800626)
- Testing
- Endoscopic Retrograde Cholangio-Pancreatography (ERCP)
- Where
- 2 sites in Italy
- Volunteers
- 1,740 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Post-ERCP Acute Pancreatitis
ESGE-Quality Improvement in Endoscopy: ERCP
The primary aim of the present study is to compare the incidence of post-ERCP pancreatitis (PEP) before and after the implementation of the QIC-guideline in 2017: "Performance measures for ERCP and endoscopic ultrasound: a…
- Trial name
- QIC_ERCP (NCT06727851)
- Where
- Germany
- Volunteers
- 1,254 people
- Sponsor
- Universität Münster
Post-ERCP Acute Pancreatitis, Non-steroid Anti-inflammatory Drugs
Rectal NSAIDs With/Without PD Stent for PEP Prevention
Pancreatitis is the most common and serious complication following post-endoscopic retrograde cholangiopancreatography (ERCP) and is associated with occasional mortality, extended hospital stays, and increased healthcare…
- Conditions
- Post-ERCP Acute Pancreatitis, Non-steroid Anti-inflammatory Drugs, Pancreatic Duct Stent Placement
- Trial name
- NCT07117318
- Testing
- NSAIDs, NSAIDs plus PDS
- Where
- 15 sites in China
- Volunteers
- 1,278 people
- Sponsor
- Air Force Military Medical University, China
Post-ERCP Acute Pancreatitis
Urine Trypsinogen 2 Dipstick for the Early Detection of Post-ERCP Pancreatitis
Post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP) is the most common, serious complication of ERCP. More than 500,000 ERCP procedures are performed from which 25,000 cases of PEP occur in the U.S.A.
- Trial name
- NCT03098082
- Testing
- Actim Pancreatitis
- Where
- United States
- Volunteers
- 394 people
- Sponsor
- Indiana University
Post-ERCP Acute Pancreatitis, Pancreatic Duct Stricture
Short Term Pancreatic Stenting Registry
The purpose of this study is to document clinical utility and distribution of indications for short term pancreatic stenting, and stent type preference by indication at tertiary referral centers with expertise in pancreatic…
- Conditions
- Post-ERCP Acute Pancreatitis, Pancreatic Duct Stricture, Pancreatic Duct Stones, Pancreatic Duct Leakage
- Trial name
- NCT02262845
- Testing
- The Advanix™ Pancreatic Stent and NaviFlex RX Pancreatic Delivery System and Pushers
- Where
- 7 sites in United States, Germany and 2 more
- Volunteers
- 246 people
- Sponsor
- Boston Scientific Corporation
Post-ERCP Acute Pancreatitis
Hemin to Prevent Post-ERCP (Endoscopic Retrograde Cholangiopancreatography) Acute Pancreatitis
ERCP (endoscopic retrograde cholangiopancreatography) has been largely demonstrated to be effective in multiple bilio-pancreatic indications.
- Trial name
- NCT01855841
- Testing
- Hemin
- Where
- 6 sites in Belgium, Taiwan
- Volunteers
- 284 people
- Sponsor
- Erasme University Hospital
Bile Duct Diseases, Biliary Tract Diseases
Safety and Efficacy Study of IL-10 (Tenovil TM) in the Prevention of Post-ERCP Acute Pancreatitis (Study P02580)(TERMINATED)
The purpose of this study is to determine if a single dose of IL-10 compared to placebo is safe and effective in reducing the incidence of post-ERCP acute pancreatitis for subjects with increased risk.
- Conditions
- Bile Duct Diseases, Biliary Tract Diseases, Gallbladder Diseases, Pancreatitis
- Trial name
- NCT00040131
- Testing
- IL-10
- Volunteers
- 316 people
- Sponsor
- Merck Sharp & Dohme LLC
Post-ERCP Acute Pancreatitis
ERCP-induced and Non-ERCP Induced Acute Pancreatitis: Two Distinct Clinical and Immunological Entities?
Post endoscopic pancreatitis (PEP) has different initial immunologic response to primary injury compared to acute pancreatitis of other etiology (non-PEP AP).
- Trial name
- NCT02602574
- Testing
- heparinized peripheral venous blood and urine sample.
- Where
- Croatia
- Volunteers
- 66 people
- Sponsor
- University Hospital Rijeka
Post-ERCP Acute Pancreatitis, Cholangitis
ERCP in Super-aged Patients Considering Difficult Cannulation: Challenges and Adverse Events
Today 11 percent of China's population is over the age of 65, and according to United Nations, it will take China just 20 years for the proportion of the elderly population to double to 25%.
- Trial name
- NCT03771547
- Testing
- ERCP
- Where
- China
- Volunteers
- 614 people
- Sponsor
- The Second Hospital of Nanjing Medical University
Post-ERCP Acute Pancreatitis
Rectal Indomethacin to Prevent Post-Endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis
The purpose of this study is to assess whether peri-procedural administration of rectal indomethacin, compared to placebo, can reduce the incidence of post-ERCP pancreatitis.
- Trial name
- NCT01774604
- Testing
- Indomethacin
- Where
- United States
- Volunteers
- 449 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Post-ERCP Acute Pancreatitis
Statins and Post-ERCP Acute Pancreatitis (Stark Project)
Post-endoscopic retrograde cholangiopancrepatography (ERCP) acute pancreatitis (PEAP) is a frequent complication of this endoscopic procedure.
- Trial name
- Stark (NCT06367322)
- Testing
- Statin
- Where
- 2 sites in Spain
- Volunteers
- 1,016 people
- Sponsor
- Hospital General Universitario de Alicante
Post-ERCP Acute Pancreatitis, Pancreatic Stent
Establishing a Sonographic Based Algorithm to Verify Pancreatic Stent Position Placed to Prevent Post-ERCP Pancreatitis Before Endoscopic Removal
The present study is a prospective, single-center study. A total of 88 patients, who had placed a pancreatic stent for preventing post-ERCP pancreatitis, will be included in the study.
- Conditions
- Post-ERCP Acute Pancreatitis, Pancreatic Stent, Ultrasound, X-rays
- Trial name
- NCT04546867
- Testing
- Sonographic based visualization of a pancreatic stent
- Where
- Germany
- Volunteers
- 88 people
- Sponsor
- Johann Wolfgang Goethe University Hospital
Post-ERCP Acute Pancreatitis
Evaluation of Post-ERCP Pain as a Predictor for Post-ERCP Pancreatitis
Pancreatitis is the most common complication after ERCP, although its frequency varies significantly depending on the study from < 2% up to 40%.
- Trial name
- PEP-PREPARE (NCT04770857)
- Testing
- Visual analogue scale
- Where
- Switzerland
- Volunteers
- 1,000 people
- Sponsor
- Nicola Frei
Choledocholithiasis With Acute Cholangitis (Diagnosis), Acute Pancreatitis Due to Gallstones
Complications After Endoscopic Retrograde Cholangiopancreatography
Retrospective study to analyze benign complications and malignancy risks after ERCP with sphincterotomy. All patients who received a ERCP with sphincterotomy for a benign disease will be included.
- Trial name
- ERCP (NCT04735224)
- Volunteers
- 500 people
- Sponsor
- Juan Carlos Martín del Olmo
Pancreatitis, Acute
Cold and NSAID Trial for Prevention of Post-ERCP Pancreatitis
The standard prophylaxis for post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP) is performed with rectal non-steroidal anti-inflammatory drugs (NSAIDs).
- Trial name
- NCT07738094
- Testing
- NSAID alone, Cryoprevention associated with NSAID
- Where
- Brazil
- Volunteers
- 583 people
- Sponsor
- Instituto do Cancer do Estado de São Paulo